Page 1 | Search Results | Blood | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

Synergistic Loss of IRF4 and Induction of IRF7 Sensitizes Primary Myeloma Cells to IMiD Killing by IFNβ in Prolonged Early G1 Arrest Induced by CDK4/CDK6 Inhibition

Xiangao Huang, PhD, David Jayabalan, B.S.M.S, Maurizio Di Liberto, Ph.D., Jackson D Harvey, B.S., Anna C. Schinzel, PhD, Tomer M Mark, MD, MSc, Mohamad Hussein, MD, Sophia Randolph, MD, PhD, William C. Hahn, MD, PhD, Ruben Niesvizky, MD, Selina Chen-Kiang, PhD

Blood (2012) 120 (21): 572.

https://doi.org/10.1182/blood.V120.21.572.572

Published: 2012

Journal Articles

A Prospective, Randomized, Chemoprevention Trial of Celecoxib for High Risk Monoclonal Gammopathy of Undetermined Significance and Asymptomatic Multiple Myeloma

Leonard J. Horwitz, MD, Beth Faiman, CNP, Paul Elson, ScD, Rachid Baz, MD, Mohamad Hussein, MD, John A Lust, MD, PhD, Paulette Mehta, MD, MPH, Frederic J. Reu, MD, Becky Habecker, Janice Reed, RN, Mary Ann Karam, RN, Robert M Dean, MD, Ronald Sobecks, MD, Eric D. Hsi, MD, Varsha Kaushal, MD, Matt Kalaycio, MD

Blood (2012) 120 (21): 5045.

https://doi.org/10.1182/blood.V120.21.5045.5045

Published: 2012

Journal Articles

Targeting the Wnt/β-Catenin Signaling Pathway and CD44-Mediated Adhesion As a Rational Approach to Overcome Lenalidomide Resistance in Multiple Myeloma

Chad C. Bjorklund, Ph.D., Sharon Lea Aukerman, PhD, Antonia Lopez-Girona, Ph.D., Mohamad Hussein, MD, Rajesh Chopra, PhD, Isere Kuiatse, Ph.D., Deborah J. Kuhn, Ph.D., Caimiao Wei, PhD, Robert Z. Orlowski, MD, PhD

Blood (2011) 118 (21): 928.

https://doi.org/10.1182/blood.V118.21.928.928

Published: 2011

Journal Articles

Long-Term Outcomes and Safety of Continuous Lenalidomide Plus Dexamethasone (Len+Dex) Treatment in Patients (Pts) with Relapsed or Refractory Multiple Myeloma (RRMM)

Meletios Athanasios Dimopoulos, MD, Mohamad Hussein, MD, Arlene S Swern, PhD, Donna M. Weber, MD

Blood (2011) 118 (21): 2929.

https://doi.org/10.1182/blood.V118.21.2929.2929

Published: 2011

Journal Articles

Lenalidomide Targets Myeloma Cells Preferentially During Prolonged Early G1 Arrest but Not Synchronization Into S Phase by Selective and Reversible Inhibition of CDK4/CDK6 through Loss of IRF-4

Xiangao Huang, Ph.D., Maurizio Di Liberto, Ph.D., David Jayabalan, B.S.M.S, Mohamad Hussein, M.D., Sophia Randolph, M.D., Ph.D., Ruben Niesvizky, M.D., Selina Chen-Kiang, Ph.D.

Blood (2010) 116 (21): 449.

https://doi.org/10.1182/blood.V116.21.449.449

Published: 2010

Journal Articles

Lenalidomide (LEN) Therapy In Combination with Dexamethasone (DEX) Is Associated with a Low Incidence of Viral Infections

Rachid Baz, MD, Sagar Lonial, MD, Mohamad Hussein, Arlene S. Swern, PhD, Meletios A. Dimopoulos, MD

Blood (2010) 116 (21): 1950.

https://doi.org/10.1182/blood.V116.21.1950.1950

Published: 2010

Journal Articles

The Combined Safety and Tolerability Profile of Vorinostat-Based Therapy for Solid or Hematologic Malignancies.

David Siegel, Pamela N Munster, Eric Rubin, Marian Iwamoto, Simon van Belle, Mohamad Hussein, MD, Chandra P Belani, Francisco Robert, Evanthia Galanis, James Hardwick, Syed Rizvi

Blood (2009) 114 (22): 1710.

https://doi.org/10.1182/blood.V114.22.1710.1710

Published: 2009

Journal Articles

Dacetuzumab (SGN-40), Lenalidomide, and Weekly Dexamethasone in Relapsed or Refractory Multiple Myeloma: Multiple Responses Observed in a Phase 1b Study.

Edward Agura, MD, Ruben Niesvizky, MD, Jeffrey Matous, MD, Nikhil Munshi, MD, Mohamad Hussein, MD, Ramakrishnan V Parameswaran, MD, Stefano Tarantolo, MD, Nancy C Whiting, PharmD, BCOP, Jonathan G Drachman, MD, Jeffrey A Zonder, MD

Blood (2009) 114 (22): 2870.

https://doi.org/10.1182/blood.V114.22.2870.2870

Published: 2009

Journal Articles

Evaluation of Single Agent Lenalidomide in Patients with Newly Diagnosed Multiple Myeloma (NDMM).

Rachid Baz, Mohamad Hussein, MD, Daniel J. Lebovic, MD, Elizabeth Finley-Oliver, RN, Mehul P Patel, MB, BS, Hong Liu, Kena C Miller, NP, Margaret Wood, Kelvin P. Lee, MD, Asher Chanan-Khan, MD

Blood (2009) 114 (22): 3868.

https://doi.org/10.1182/blood.V114.22.3868.3868

Published: 2009

Journal Articles

Full Dose of Lenalidomide for 12 Months Followed by a Lower Maintenance Dose Improves Progression-Free Survival in Patients with Relapsed/Refractory Multiple Myeloma.

Meletios A Dimopoulos, Mohamad Hussein, Arlene S. Swern, Donna Weber

Blood (2009) 114 (22): 2874.

https://doi.org/10.1182/blood.V114.22.2874.2874

Published: 2009

Journal Articles

Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma

Paul Richardson, Sundar Jagannath, Mohamad Hussein, James Berenson, Seema Singhal, David Irwin, Stephanie F. Williams, William Bensinger, Ashraf Z. Badros, Robert Vescio, Laurie Kenvin, Zhinuan Yu, Marta Olesnyckyj, Jerome Zeldis, Robert Knight, Kenneth C. Anderson

Blood (2009) 114 (4): 772–778.

https://doi.org/10.1182/blood-2008-12-196238

Published: 2009

Journal Articles

CS1: A Potential New Therapeutic Target for the Treatment of Multiple Myeloma.

Eric D. Hsi, MD, Roxanne Steinle, BA, Balaji Balasa, PhD, Aparna Draksharapu, MS, Benny Shum, MS, Marukh Huseni, BS, David Powers, PhD, Amulya Nanisetti, MS, Marna Williams, PhD, Vladimir Vexler, PhD, Mohamad Hussein, MD, Daniel Afar, PhD

Blood (2006) 108 (11): 3457.

https://doi.org/10.1182/blood.V108.11.3457.3457

Published: 2006

Journal Articles

A Randomized, Double-Blind, Placebo-Controlled Trial of Thalidomide Plus Dexamethasone Versus Dexamethasone Alone as Primary Therapy for Newly Diagnosed Multiple Myeloma.

S. Vincent Rajkumar, MD, Mohamad Hussein, John Catalano, Wieslaw Jedrzejcak, Svetlana Sirkovich, Marta Olesnyckyj, Zhinuan Yu, Robert Knight, Jerry Zeldis, Joan Blade

Blood (2006) 108 (11): 795.

https://doi.org/10.1182/blood.V108.11.795.795

Published: 2006

Journal Articles

CD28-Mediated Regulation of Multiple Myeloma Cell Proliferation and Survival.

Kelvin P. Lee, MD, Nizar J. Bahlis, MD, Anne M. King, MS, Despina Kolonias, BS, Louise M. Carlson, BS, Mohamad Hussein, MD, Howard Terebolo, DO, Gerald E. Byrne, Jr., MD, Bruce L. Levine, Ph.D, Lawrence H. Boise, Ph.D

Blood (2005) 106 (11): 355.

https://doi.org/10.1182/blood.V106.11.355.355

Published: 2005

Journal Articles

Doxil, Vincritine, Reduced Frequency Dexamethasone in Combination with Thalidomide (DVd-T) Is Associated with Higher Overall and Progression Free Survival as Compared to DVd in Patients with Multiple Myeloma (MM).

Khaldoun Almhanna, MD, MPH, Revathi Suppiah, MD, Rachid Baz, MD, Mary Ann Karam, Beth Faiman, CNP, MSN, Janice Reed, RN, Mohamad Hussein, MD

Blood (2005) 106 (11): 2557.

https://doi.org/10.1182/blood.V106.11.2557.2557

Published: 2005

Journal Articles

A Multicenter, Single-Arm, Open-Label Study To Evaluate the Efficacy and Safety of Single-Agent Lenalidomide in Patients with Relapsed and Refractory Multiple Myeloma; Prelininary Results.

Paul Richardson, MD, Sundar Jagannath, MD, Mohamad Hussein, MD, James Berenson, MD, Seema Singhal, MD, David Irwin, MD, Stephanie F. Williams, MD, William Bensinger, MD, Ashraf Z. Badros, MD, Robert Vescio, MD, Laurie Kenvin, BSN, Zhinuan Yu, PhD, Marta Olesnyckyj, RN, BSN, Herbert Faleck, DO, Jerome Zeldis, MD, Robert Knight, MD, Kenneth C. Anderson, MD

Blood (2005) 106 (11): 1565.

https://doi.org/10.1182/blood.V106.11.1565.1565

Published: 2005

Journal Articles

Aggressive Electrolytes Replacement in Multiple Myeloma (MM) Patients Receiving Arsenic Trioxide (ATO) Containing Regimens Alleviates the Need for Frequent Electrocardiogram (ECG) Monitoring.

Toni K. Choueiri, MD, Esteban Walker, PhD, Rachid C. Baz, MD, Rony M. Abou-Jawde, MD, Snehal G. Thakkar, MD, Bridget McGowan, Megan Kelly, Steven Andresen, MD, Mohamad Hussein, MD

Blood (2005) 106 (11): 5155.

https://doi.org/10.1182/blood.V106.11.5155.5155

Published: 2005

Journal Articles

A Phase II Trial of Doxil, Vincristine and Reduced Schedule Dexamethasone (DVd) for Patients with Relapsed or Refractory Multiple Myeloma.

Paul Masci, D.O., Mary A. Karam, R.N., Luba Platt, B.S., Steven Andresen, D.O, Alan Lichtin, M.D., Bridget McGowan, B.S., Mohamad Hussein, M.D.

Blood (2004) 104 (11): 2415.

https://doi.org/10.1182/blood.V104.11.2415.2415

Published: 2004

Journal Articles

Apo2L/TRAIL and Bcl-2–related proteins regulate type I interferon–induced apoptosis in multiple myeloma

Quan Chen, Bendi Gong, Ashraf S. Mahmoud-Ahmed, Aimin Zhou, Eric D. Hsi, Mohamad Hussein, Alexandru Almasan

Blood (2001) 98 (7): 2183–2192.

https://doi.org/10.1182/blood.V98.7.2183

Published: 2001

NARROW

Synergistic Loss of IRF4 and Induction of IRF7 Sensitizes Primary Myeloma Cells to IMiD Killing by IFNβ in Prolonged Early G1 Arrest Induced by CDK4/CDK6 Inhibition

A Prospective, Randomized, Chemoprevention Trial of Celecoxib for High Risk Monoclonal Gammopathy of Undetermined Significance and Asymptomatic Multiple Myeloma

Targeting the Wnt/β-Catenin Signaling Pathway and CD44-Mediated Adhesion As a Rational Approach to Overcome Lenalidomide Resistance in Multiple Myeloma

Long-Term Outcomes and Safety of Continuous Lenalidomide Plus Dexamethasone (Len+Dex) Treatment in Patients (Pts) with Relapsed or Refractory Multiple Myeloma (RRMM)

Lenalidomide Targets Myeloma Cells Preferentially During Prolonged Early G1 Arrest but Not Synchronization Into S Phase by Selective and Reversible Inhibition of CDK4/CDK6 through Loss of IRF-4

Lenalidomide (LEN) Therapy In Combination with Dexamethasone (DEX) Is Associated with a Low Incidence of Viral Infections

The Combined Safety and Tolerability Profile of Vorinostat-Based Therapy for Solid or Hematologic Malignancies.

Dacetuzumab (SGN-40), Lenalidomide, and Weekly Dexamethasone in Relapsed or Refractory Multiple Myeloma: Multiple Responses Observed in a Phase 1b Study.

Evaluation of Single Agent Lenalidomide in Patients with Newly Diagnosed Multiple Myeloma (NDMM).

Full Dose of Lenalidomide for 12 Months Followed by a Lower Maintenance Dose Improves Progression-Free Survival in Patients with Relapsed/Refractory Multiple Myeloma.

Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma

CS1: A Potential New Therapeutic Target for the Treatment of Multiple Myeloma.

A Randomized, Double-Blind, Placebo-Controlled Trial of Thalidomide Plus Dexamethasone Versus Dexamethasone Alone as Primary Therapy for Newly Diagnosed Multiple Myeloma.

CD28-Mediated Regulation of Multiple Myeloma Cell Proliferation and Survival.

Doxil, Vincritine, Reduced Frequency Dexamethasone in Combination with Thalidomide (DVd-T) Is Associated with Higher Overall and Progression Free Survival as Compared to DVd in Patients with Multiple Myeloma (MM).

A Multicenter, Single-Arm, Open-Label Study To Evaluate the Efficacy and Safety of Single-Agent Lenalidomide in Patients with Relapsed and Refractory Multiple Myeloma; Prelininary Results.

Aggressive Electrolytes Replacement in Multiple Myeloma (MM) Patients Receiving Arsenic Trioxide (ATO) Containing Regimens Alleviates the Need for Frequent Electrocardiogram (ECG) Monitoring.

A Phase II Trial of Doxil, Vincristine and Reduced Schedule Dexamethasone (DVd) for Patients with Relapsed or Refractory Multiple Myeloma.

Apo2L/TRAIL and Bcl-2–related proteins regulate type I interferon–induced apoptosis in multiple myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only